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Radiation resistance is a hallmark of human melanoma,
and yet mechanisms underlying this resistance are not
well understood. We recently established the role of
ATF2 in this process, suggesting that stress kinases,
which contribute to regulation of ATF2 stability and
activity, play an important role in the acquisition of such
resistance. Here we demonstrate that changes in the
expression and respective activities of TRAF2/GCK
occur during melanoma development and regulate its
sensitivity to UV-induced apoptosis. Comparing early-
and late-stage melanoma cells revealed low expression of
TRAF2 and GCK in early-stage melanoma, which
coincided with poor resistance to UV-induced, TNF-
mediated apoptosis; forced expression of GCK alone or
in combination with TRAF2 eciently increased JNK
and NF-kB activities, which coincided with increased
protection against apoptosis. Conversely, forced expres-
sion of the dominant negative form of TRAF2 or GCK in
late-stage melanoma cells reduced NF-kB activity and
decreased Fas expression, resulting in a lower degree of
UV-induced, Fas-mediated cell death. Our results
illustrate a mechanism in which protection from, or
promotion of, UV-induced melanoma cell death depends
on the nature of the apoptotic cascade (TNF or Fas) and
on the availability of TRAF2/GCK, whose expression
increases during melanoma progression. Oncogene (2000)
19, 933 – 942.
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Introduction
Malignant melanoma is among few tumor types whose
incidence has exponentially increased over the past
decade. Whereas melanoma cells are shown to respond
poorly to chemotherapy and g-irradiation, the nature
of melanoma protection from radiation induced
apoptosis remain largely unknown (Meier et al.,
1998). Mechanisms underlying the regulation of
apoptosis have revealed the role of death receptors
such as Fas, TNFR1, DR-3, TRAIL-R1 and TRAIL-
R2, which are selectively initiated upon interaction
with their respective ligands (Ashkenazi and Dixit,
1998; Nagata, 1997). Common to these receptors is the
ability to activate caspase cascades (Thornberry and
Lasebnik, 1998). The ability to resist apoptosis, by re-
arranging the apoptosis machinery, is characteristic of
most tumor cells, including melanomas (Peli et al.,
1999). Altered susceptibility to apoptosis could include
suppression of death receptor or increased expression
or activation of inhibitory apoptosis proteins (IAP’s)
that inhibit caspase activity (Deveraux and Reed,
1999). Late-stage melanoma cells express a large subset
of growth factors cytokines and their respective
receptors (including TNFa/TNFR1), which contribute
to autocrine and paracrine regulation of their progres-
sion (Moretti et al., 1999). TNFa-TNFR1 interaction
elicits either death- or survival-signaling cascades in
which the signal adaptor TNFR-associated factor
(TRAF2) plays a primary regulatory role (Arch et
al., 1998; Chaudhuri et al., 1999; Chan et al., 1999).
TRAF2 itself has been implicated in the activation of
two distinct signaling mechanisms, the NF-kB and the
p38/JNK pathways (Carpentier et al., 1998; Hsu et al.,
1996; Liu et al., 1996; Natoli et al., 1997, 1998a;
Nishitoh et al., 1998; Reinhard et al., 1997; Yuasa et al.,
1998). TNF-induced NF-kB activation can be mediated
via the adaptor receptor interacting protein (RIP), or by
the NF-kB-inducing kinase (NIK) (Galibert et al., 1998;
Kelliher et al., 1998; Lin et al., 1998; Malinin et al.,
1997; Song et al., 1997; Ting et al., 1996). NIK activates
a multiprotein catalytic complex (IkB kinase complex)
that phosphorylates the NF-kB inhibitor, IkBa, at
serines 32 and 36 (Baldwin, 1996; Zandi et al., 1997).
Phospho-IkBa is then targeted for proteasome-depen-
dent degradation (Maniatis, 1999) via the HOS/Skip1/
Cullin1/Roc1 ubiquitin ligase complex (Fuchs et al.,
1999; Tan et al., 1999), thus liberating NF-kB, which
enters the nucleus and mediates NF-kB-dependent
transcription. The other TRAF2-mediated pathway,
which is independent of NIK, activates the c-Jun
amino-terminal kinases/stress activated protein kinases
(JNKs/SAPKs/p38), a family of Ser/Thr protein kinases
regulated by extracellular signals. The Ser/Thr protein
kinases stimulate transcription by phosphorylation and
activation of a number of transcription factors,
including c-Jun, activating transcription factor 2
(ATF2), p53, and ternary complex factor (TCF)/
ELK2 (Huang et al., 1999; Fuchs et al., 1998; Ip and
Davis, 1998; Minden and Karin, 1997). Activation of
SAPK and p38 by TRAF2 is mediated by germinal
center kinase (GCK), which associates with both
TRAF2 and MEKK1 via its COOH-terminal regulatory
domain (Yuasa et al., 1998; Shi and Kehrl, 1997). While
GCK and RIP are proximal components of TRAF2-
mediated SAPK activation, RIP is a primary mediator
of TRAF2 activation of p38 (Yuasa et al., 1998).
Fas receptor cross-linking induces apoptosis in a
caspase-dependent manner (Nagata, 1997), which has
been also implicated in the cleavage and intracellular
redistribution of MEKK1 (Deak et al., 1998) and JNK
activation (Brenner et al., 1997; Goillot et al., 1997).
Among possible mechanisms for JNK activation via
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Fas is interaction with Daxx (Yang et al., 1997), which
disrupts the intramolecular inhibition of ASK1, leading
to the activation of MKK7/JNK. ASK1 has also been
implicated in TRAF2-mediated activation of stress
kinases, as well as other GCK family members
including GLK and GCKR(KHS) (Shi et al., 1999).
JNK has been also implicated in the regulation of cell
death through the Fas cascade, via its control of the
expression of Fas ligand (FasL) through an MEKK1-
regulated element on the FasL promoter (Faris et al.,
1998a, b). Interestingly, the activation of FasL is also
NF-kB and AP1-dependent (Kasibhatla et al., 1998),
pointing to a potential link between TRAF2 and FasL.
Through its diverse downstream targets and respec-
tive kinases, NF-kB (NIK/RIP) and JNK/p38 (GCK/
RIP), TRAF2 has been implicated as a critical
component of the cell’s ability to undergo programmed
cell death in response to TNF treatment or UV-
irradiation (Tobin et al., 1998). In the present study we
have addressed the contribution of TRAF2/GCK to
the regulation of AP1 and NF-kB activities and their
roles in melanoma resistance to UV-irradiation.
In elucidating transcription factors that alter mela-
noma resistance to UV-irradiation we have identified
CREB associated proteins (Yang et al., 1996) and
ATF2 as factors that play an important role in
acquiring this resistance (Ronai et al., 1998). More
recent studies have identified that hypo-phosphorylated
or transcriptionally inactive forms of ATF2 elicit a
silencing eect on TNFa expression, which mediates an
anti-apoptotic signal in LU1205, a late-stage melanoma
cell line, resulting in increased apoptosis of these cells
(Ivanov and Ronai, 1999). To further elucidate
upstream cellular components that govern apoptosis
in melanoma cells, we have studied the functional
regulation of TRAF2/GCK and its eectors AP1 and
NF-kB in LU1205 as well as in an early-phase
melanoma-derived cell line, WM1552. Our studies
identify the role of TRAF2 and its respective eectors
GCK/NF-kB in regulation of UV-mediated apoptosis
of early- and late-stage melanoma cells. Our studies
also demonstrate that TRAF2/GCK’s ability to elicit
protection from or promotion of UV-induced apopto-
sis coincides with the existence of TNF or Fas
apoptotic signaling cascades, respectively.
Results
Distinct stress response pathways in WM1552 early- vs
LU1205 late-phase melanoma derived cells
To elucidate kinase signaling cascades and transcrip-
tion factors that may contribute to regulation of UVC-
induced apoptosis in human melanoma, we compared
vertical growth-phase WM1552 melanoma cells, which
represent an early-phase melanoma, with the highly
tumorigenic LU1205 cells, which represent a late-phase
melanoma (Satyamoorthy et al., 1997). Analysis of
UVC-activated kinases and their respective substrates
revealed higher basal levels of phospho-p38 and
phospho-ATF2 in LU1205 cells, yet both WM1552
and LU1205 cells exhibited similar levels of phospho-
MKK6/p38/ATF2 after UV-irradiation (Figure 1a).
WM1552 cells exhibit a lesser degree of MKK7
phosphorylation as well as JNK and c-Jun expres-
sion/phosphorylation before and after UVC irradiation
(Figure 1b). TRAF2, a key regulator of diverse stress
signaling, is expressed at lower levels in WM1552 cells
as compared to LU1205 cells (Figure 1b). Further-
more, in response to UVC irradiation WM1552, but
not LU1205 cells, showed a time-dependent decrease in
TRAF2 (which completely disappeared after 16 h; not
shown). Whereas LU1205 cells exhibit elevated-
WM1552 cells showed decreased- TNFR1 expression
levels after UV-irradiation (Figure 1b).
Given the changes in TRAF2 expression, we also
monitored DNA-binding activity of NF-kB p65 – p50,
which is a putative TRAF2 eector (Hsu et al., 1996;
Liu et al., 1996). EMSA revealed a markedly lower
NF-kB activity (even after UVC treatment) in
WM1552 cells, as compared with LU1205 cells (Figure
1c). NF-kB-, ATF2/cJun- and AP-1-dependent tran-
scription, using the corresponding luciferase reporter
constructs, reflected the observations made at the level
of expression and phosphorylation: up-regulation
(4threefold) of NF-kB-dependent transcription was
observed in LU1205 but not in WM1552 cells
following UVC treatment (Figure 1d upper panel).
Similarly, high basal levels of AP-1 (Jun-Fos)-depen-
dent transcription observed in LU1205 cells increased
further after UVC treatment, whereas WM1552 cells
exhibited almost ten times lower AP1 activity before
and after UVC treatment (Figure 1d, lower panel).
Conversely, both early- and late-phase melanoma cells
had similar basal levels of ATF2-Jun-dependent
transcription. After UVC irradiation a greater increase
was observed in the LU1205 cells (twofold over
WM1552; Figure 1d, upper panel). Taken together,
these findings identify impaired NF-kB- and MKK7/
JNK/Jun activity in early-phase melanoma cells before
and after UVC irradiation, whereas a high degree of
UVC-induced MKK6/p38/ATF2 phosphorylation was
seen in both early- and late-phase melanoma cells.
TRAF2, which has been implicated in the regulation
of GCK/MEKK1-dependent AP1 and NF-kB path-
ways (Hsu et al., 1996; Reinhard et al., 1997; Yuasa et
al., 1998), exhibits lower basal expression and shorter
expression in response to UV-irradiation in the early-
phase melanoma cells.
WM1552 early- and LU1205 late-phase melanoma cells
exhibit different sensitivity to UV-irradiation and utilize
alternate programmed cell death pathways
LU1205 cells exhibit a lower degree of UVC-induced
apoptosis (determined by DNA fragmentation analysis)
40 h after UVC irradiation, when compared with
WM1552 cells (24% vs 38%, respectively; Figure 2a).
Furthermore, WM1552 cells were sensitive to apoptosis
induced by the combination of exogenous TNFa and
cycloheximide (CHX), whereas LU1205 cells were
relatively stable under these conditions (Figure 2c).
Marked dierences between WM1552 and LU1205
cells in surface Fas levels were observed using flow
cytometric analysis (Figure 2d).
To determine which of the two (Fas/TNFR1)
primary apoptotic pathways governs UV-induced cell
death, cells were treated with antagonistic antibodies to
Fas or TNFa prior to UV-exposure. Based on a dose
dependent calibration analysis (not shown) we used
5 mg/ml of antagonistic antibodies to study eects on
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each of the two respective pathways. Although
antagonistic antibodies to Fas and to TNF reduced
degree of UV-induced early-phase apoptosis (deter-
mined by Annexin-V staining) of WM1552 cells,
antagonistic antibodies to TNF were more ecient as
they completely suppressed UV-induced apoptosis in
these cells (Figure 2b). Analysis of apoptosis in
LU1205 melanoma cells revealed that UVC irradiation
induced Fas-mediated apoptosis of these cells (Ivanov
and Ronai, 1999; Figure 2b). These observations
suggest that unlike the Fas-dependent pathway found
in LU1205 cells, UVC induces TNFR- as well as Fas-
dependent apoptosis of WM1552 cells.
TRAF2 elicits different effects on UVC-induced apoptosis
of early vs late-stage melanoma cells
Given the changes observed in TRAF2 expression when
early and late-phase melanomas were compared, we
elucidated TRAF2’s contribution to apoptosis of early-
and late-phase human melanoma cells. To this end we
expressed wild type and a dominant negative form of
TRAF2 (deleted of the first 86 amino acids (Hsu et al.,
1996) comprising the ring finger domain; TRAF2DN).
Overexpression of TRAF2DN in LU1205 cells (stable
transfection) reduced basal and UVC-induced expres-
sion of Fas, as detected by Western analysis (Figure 3a)
and flow cytometry (Figure 3b), and reduced UVC-
induced levels of FasL expression (Figure 3a).
Decreased Fas/FasL expression in LU1205/TRAF2DN
cells coincided with a two-fold decrease in UVC-
induced apoptosis (measured by Annexin-V staining),
compared to LU1205-neo cells (Figure 3c). DNA
fragmentation analysis further confirmed dierence in
the apoptosis levels of these two cell lines (37% in
LU1205-neo vs 25% in LU1205/TRAF2DN cells) 40 h
after UVC irradiation (Figure 3d).
As NF-kB has been implicated in the regulation of
the Fas and FasL promoters (Chan et al., 1999;
Kasibhatla et al., 1998) decreased Fas and FasL
expression levels may be attributed to TRAF2DN-
dependent down-regulation of NF-kB activity, as we
have observed for LU1205/TRAF2DN cells (Ivanov
and Ronai, unpublished observations).
Forced expression of TRAF2DN in WM1552 cells
further suppressed NF-kB (Figure 4a), but not ATF2-
Figure 1 Altered expression and activity of TRAF2 and its related stress kinases and transcription factors in UVC-treated early- vs
late-stage melanoma. (a,b) Total cell extracts were prepared as described under Materials and methods, and 75 mg of protein was
separated by SDS-electrophoresis in 10% polyacrylamide gel. The same membrane was probed sequentially with Abs against
phosphoprotein and non-phosphoprotein, including MAPK, p38, ATF2, JNK, c-Jun, as well as TNFR1/p55, phospho-MKK6,
phospho-MKK7, and TRAF2 as indicated. (c) EMSA of nuclear extracts of WM1552 and LU1205 cells was performed using a 32P-
labeled NF-kB-binding oligonucleotide. The specificity of the reaction was confirmed using 50-fold excess of cold NF-kB-binding
oligonucleotide or non-related NF-Y-binding oligonucleotide. Pretreatment of nuclear extracts with Abs to NF-kB subunits p65 and
p50 was also performed, as indicated. Arrows indicate the position of the NF-kB p65 – p50 DNA-binding complex, two non-specific
(ns) bands and free oligonucleotide probe (FP). (d) Determination of NF-kB-, AP-1 and ATF2-Jun-dependent transcription in
WM1552 and LU1205 cells. 56105 cells were transiently transfected with 0.5 mg of reporter construct (26NF-kB-Luc, 56TREtk-
Luc, 56Jun2tk-Luc or control tk-Luc) plus 0.25 mg of pCMV-b-gal. Twenty-four hours after transfection cells were irradiated with
UVC (60 J/m2). After an additional 18 h, irradiated and nontreated cells were analysed for luciferase and b-galactosidase activity.
The normalized ratio of luciferase activity to b-galactosidase is shown
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Jun transactivation (Figure 4b). In order to evaluate
the possible role of TRAF2 in the regulation of
apoptosis in early-phase melanoma cells, TRAF2DN
or full-length TRAF2 was transiently co-transfected
with green fluorescent protein (GFP) expression
construct into WM1552 cells. Attenuation of TRAF2
signaling by TRAF2DN in GFP-positive cells further
increased levels of basal and UVC-induced apoptosis
as determined by DNA fragmentation analysis (Figure
4c). These findings point to the protective role of
TRAF2 against TNF-mediated apoptosis of WM1552
cells. However, amount of TRAF2DN required to elicit
almost maximal changes in the level of UV-induced
apoptosis (0.2 mg, Figure 4c) was not sucient to
mediate respective changes in NF-kB activity (Figure
4a), suggesting that other cellular eectors may also
contribute to TRAF2 ability to alter sensitivity of
WM1552 cells to UV-induced apoptosis. Along the
same line, overexpression of full-length TRAF2 did not
markedly change levels of apoptosis (data is shown
below in Figure 5f), suggesting that TRAF2’s ability to
elicit protection requires cooperation with other
cellular components.
These observations suggest that TRAF2 elicits a pro-
apoptotic signal in UV-treated LU1205 cells (via the
Fas pathway), as opposed to the anti-apoptotic signal
identified in UV-irradiated WM1552 cells (mediated by
the TNF/Fas pathways).
GCK is a key player in UVC-mediated apoptosis of
human melanoma cells
In light of the role identified for TRAF2 in UVC-
mediated apoptosis of human melanoma cells, we
elucidated the possible eects of the proximal TRAF2
eector, GCK (Kyriakis, 1999). We focused on GCK
since this protein has been implicated in the link
between TRAF2 and MEKK1, thereby eliciting
TRAF2 signals to both JNK/AP1 and IKK/NF-kB
pathways (Kyriakis, 1999).
Western blot analysis revealed low expression of GCK
in cultured melanocytes (which are grown in the presence
of TPA) and very low (almost undetectable) expression
in two early-phase melanoma cells, WM1552 and
WM1560 (Figure 5a,b). Somewhat higher expression
levels of GCK were observed in the intermediate-phase,
WM35 melanoma cells (Figure 5b). Of five late-phase
melanoma lines tested (the three shown in Figure 5a and
b are LU1205, THX and FEMX), all exhibited high
expression level of GCK. Thus, analysis of eight
Figure 2 UVC-induced dierent level and type of apoptosis when early and late-stage melanoma cells are compared. (a) DNA
fragmentation analysis of LU1205 and WM1552 melanoma cells was performed 40 h after UVC irradiation (60 J/m2). The
percentage of cells in gate 1 indicated the level of apoptotic cells with hypodiploid DNA content. (b) The levels of early apoptosis
were determined 18 h after UVC treatment using Annexin-V staining and flow cytometry. Antagonistic anti-Fas, anti-TNFa Abs, or
control normal mouse IgG (5 mg/ml) was introduced into the media 1 h before UVC irradiation of WM1552 cells. (c) WM1552 and
LU1205 cells were treated with cycloheximide alone (CHX) (10 mg/ml) or with TNFa plus CHX. DNA fragmentation analysis was
performed 40 h after treatment. (d) Surface Fas expression of melanoma cells was detected using anti-Fas-PE mAb and flow
cytometry. Mean fluorescence intensity is indicated
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melanoma-derived cell lines and a culture of normal
melanocytes point to an increase in GCK expression,
which coincides with melanoma progression. Since GCK
association with TRAF2 requires its ability to elicit
signal from TRAF2 to MEKK1 we have examined
TRAF2/GCK association in both early and late-phase
melanoma cells. While a TRAF2/GCK complex was
identified in all late-phase melanoma cells subjected to
UV-irradiation, it was poorly detectable in the early-
phase WM1552 cells (not shown).
Parallel analysis of BclxL, a universal anti-apoptotic
protein (Adams and Cory, 1998) revealed a high level
of expression in both early and late-phase melanoma
cells (Figure 5a). Conversely, BclxS was poorly
expressed in the WM1552 cells (Figure 5a), when
compared with the late-stage melanoma cells tested
here. These observations suggest that other apoptotic
regulatory proteins should be altered in the early-stage
melanoma cells.
Since poor expression of GCK may explain impaired
NF-kB and AP1 activities (Figure 1) and could
contribute to greater sensitivity of early-phase melano-
ma to UV-irradiation we have tested whether expres-
sion of exogenous GCK could restore some of these
phenotypes. To this end, WM1552 cells were trans-
fected with the GCK expression construct (Figure 5c)
and the levels of NF-kB- and AP1-dependent tran-
scription were monitored using respective luciferase
reporters. Forced expression of GCK in WM1552 led
to a dose-dependent increase in NF-kB and AP1/Jun
transcriptional activities (Figure 5d). Expression of
exogenous GCK also caused a marked decrease in
TNFa-induced apoptosis (Figure 5e). Forced expres-
sion of GCK reduced degree of UV-induced cell death.
Further increase in the protection of WM1552 cells
against UV-induced apoptosis was seen upon co-
expression of GCK and TRAF2, although forced
expression of TRAF2 alone did not elicit such
protection (Figure 5f). Conversely, co-transfection of
the stable NF-kB inhibitor, IkBDN, abolished the anti-
apoptotic eect of GCK (Figure 5f). These observa-
tions suggest that GCK elicit protection of early-phase
melanoma cells from UV-irradiation, which is NF-kB-
dependent. These observations also imply that im-
paired GCK expression in early-phase melanoma cells
is the primary cause for the low level of NF-kB/AP1
activities and weak resistance to UV-irradiation.
Dominant-negative GCK reduces NF-kB activity and
UV-induced apoptosis in late-stage melanoma cells
The finding that increased GCK expression contributes
to elevated resistance of early-phase melanoma cells to
UV-irradiation prompted us to test whether inhibition
of GCK activities in late-stage melanoma cells would
alter their high resistance to irradiation, which is
characteristic of these cells. Forced expression of
GCKK-H, a dominant-negative form of GCK, in the
Figure 3 Down-regulation of UVC-induced Fas-mediated apoptosis in LU1205/TRAF2DN cells. (a) Western blot analysis of
TRAF2DN, Fas and FasL expression in LU1205-neo and LU1205/TRAF2DN cells before and 6 h after UVC treatment. (b) Surface
expression of Fas was detected by flow cytometry in LU1205-neo and LU1205/TRAF2DN. (c) Dose-response study of UVC-
induced apoptosis of LU1205-neo and LU1205/TRAF2DN cells 16 h after treatment. The apoptosis levels were determined using
annexin-V-FITC staining and flow cytometry. (d) DNA fragmentation analysis of LU1205-neo and LU1205/TRAF2DN cells was
performed 40 h after UVC irradiation (60 J/m2). The percentage of cells in gate 1 indicates the level of apoptotic cells with
hypodiploid DNA content. These experiments were repeated more than five times with similar results
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late-stage LU1205 melanoma cells decreased the degree
of UV-induced apoptosis (from 47 to 28%) in LU1205
cells (Figure 6a). This finding confirms the contribution
of GCK to radiation resistance of both early- and late-
phase melanoma cells.
Given the ability to abrogate GCK eect on
resistance of early-phase melanoma cells by the use
of IkBDN, we have tested whether dominant negative
GCK alters level of NF-kB activity in the late-stage
melanoma cells. As shown in Figure 6b, forced
expression of GCKK-H caused a dose dependent
decrease in NF-kB-mediated transcription before and
after UV-irradiation (Figure 6b). This finding suggests
that GCK plays a positive role in the activation of NF-
kB in UV-irradiated late stage melanoma cells, as well
as in normal growing cells. Since NF-kB has been
implicated in regulation of Fas mediated-death, this
finding is in agreement with the notion that in these
late-phase melanoma cells UV-induced death is Fas-
dependent. Accordingly, reduced NF-kB activity and
Fas expression is expected to also decrease degree of
Fas-mediated cell death, as indeed seen (Figure 6a).
Conversely, dominant negative GCK did not reduce,
but rather caused an increase in 56Jun2 derived
luciferase activity (Figure 6c). Since this reporter is
regulated by the Jun-ATF2 heterodimer, it is possible
that GCK primarily aected one of the two possible
upstream kinases, JNK or p38, thereby allowing a
greater input from ATF2 phosphorylation. Analysis of
p38 signaling revealed that in both early- and late-
phase melanoma cells p38 elicits an anti-apoptotic
signal, which could be attenuated by the pharmacolo-
gical inhibitor SB203580 (not shown). Accordingly,
since reduced p38 should have been reflected in
increased level of apoptosis, which is not the case, it
is likely that the dominant negative GCK decreased
JNK but not p38 activities.
Discussion
The present study identifies changes in expression of
TRAF2/GCK during melanoma progression and
demonstrates the intriguing ability of TRAF2/GCK
to elicit either protection from or promotion of UVC-
induced apoptosis. Through the analysis of eight
melanoma cells lines, which represent early and late-
phases in melanoma progression, we highlight the role
of TRAF2 in conferring sensitivity or resistance of
melanoma cells to UV-induced apoptosis. Our findings
suggest that such regulation depends upon: (a) the
expression level of TRAF2, after exposure to UV
irradiation; (b) level of GCK expression, a critical link
between TRAF2 and MEKK1/NF-kB/AP1, and; (c)
the apoptotic cascade (TNF/Fas), which mediates UV-
response of the particular melanoma cell studied. The
current study further demonstrates the ability to alter
melanoma resistance to irradiation upon changes in
TRAF2-eectors, GCK and NF-kB.
Our study identifies that the availability of GCK is
essential for the ability of TRAF2 to elicit protection
of melanoma cells from apoptosis. GCK has been
implicated in TRAF2-mediated MEKK1 activation,
thereby regulating both AP1 and NF-kB pathways
(Kyriakis, 1999; Lee et al., 1998; Yuasa et al., 1998).
Poor expression levels of GCK in the early-phase
melanoma cells have been identified as the primary
reason for impaired JNK and NF-kB activity. Forced
expression of GCK in these cells eciently restored
expression and activity of both AP1 and NF-kB, which
was sucient to elicit protection of these cells from
UV-induced TNF-mediated apoptosis. Lower expres-
sion of GCK was seen in 2/2 early melanoma cell lines,
as well as in normal cultured melanocytes, suggesting
that increased expression of GCK found in late-phase
melanoma cells plays an important role in mediating
melanoma resistance to UV-irradiation. Indeed, forced
expression of dominant negative GCK in late-phase
melanoma cells reduced the fraction of apoptotic cells
in response to UV-irradiation, possibly due to
decreased NF-kB activity and NF-kB-dependent Fas
expression, thus by blocking the primary apoptotic
cascade in these late-stage melanoma cells. In as much,
this study is the first to document changes in GCK
expression during tumor progression, as shown here
for melanoma cells, and to implicate GCK in UV-
induced programmed cell death. Identifying the
mechanisms underlying the regulation of GCK expres-
Figure 4 Eects of dominant negative TRAF2 on transcription
and apoptosis of early-phase melanoma cells. (a, b) WM1552 cells
were co-transfected with TRAF2DN, b-gal and 26NF-kB-Luc or
56Jun2tk-Luc constructs and cells were subjected to sham (no
UVC) or irradiation (UVC; 60 J/m2) after 24 h. Degree of
transactivation was determined after an additional 18 h; level of
luciferase activity has been normalized to the degree of b-gal. (c)
Percent of apoptotic cells in UV-treated WM1552 cells that
express TRAF2DN and GFP. Forty-eight hours after transfec-
tion, cells were irradiated with UVC (60 J/m2). After an
additional 18 h analysis of DNA fragmentation of GFP+ cells
was performed
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sion and stability is key to understanding the nature of
changes identified in the present studies.
While our analysis was carried out on two early, one
intermediate and five late-stage melanoma derived cell
lines it is important to confirm the pattern identified
here in additional melanoma as well as other tumor
types. Given the poor growth rate and complicated
growth conditions (which often causes stress, an
unwarranted situation for studying stress response) of
early-stage melanoma cultures, further analysis should
preferentially rely on freshly dissected tumor samples.
The intriguing ability of TRAF2/GCK to elicit either
protection or promotion of UVC-induced apoptosis
may be in line with TRAF2-dependent or -independent
regulation of NF-kB, as implicated from findings in
TRAF2 null cells (Yeh et al., 1997), as in lymphocytes
expressing the dominant negative form of TRAF2 (Lee
et al., 1997). The latter is supported by the observation
that forced expression of GCK, but not TRAF2, was
sucient to induce NF-kB activities in WM1552 cells,
whereas combined expression of TRAF2 and GCK
further increased NF-kB activities. Along these lines,
expression of dominant negative form of TRAF2 in the
late-stage melanoma cells had small eect on NF-kB
transcriptional activities (not shown), whereas domi-
nant negative GCK eectively blocked NF-kB activ-
ities, suggesting that NF-kB activities in both early-
and late-phase melanoma cells are GCK-dependent
and that GCK eects may not completely overlap with
those elicited by TRAF2. GCK eect on NF-kB
appears to be cell type specific, as it was not seen in
the HEK293 cells (Shi and Kehrl, 1997).
The eects elicited by TRAF2/GCK on UV-induced
apoptosis identify TRAF2 and GCK as central
regulators of melanoma susceptibility to UV-induced
apoptosis. While our results point toward the role of
GCK in the ability of TRAF2 to dictate the
susceptibility to UV-induced apoptosis, the contribu-
tion of other components of TRAF-dependent signal-
ing, including RIP, NIK and Siah1a (Yuasa et al.,
1998; Song et al., 1997; Ting et al., 1996), as well as
other TRAF family members is yet to be determined.
The nature of TRAF2/GCK eectors may explain the
diverse (anti/pro) apoptotic signaling attributed to
TNF/TRAF2 (reviewed in Natoli et al., 1998b), and
which was also observed in the current study.
In all, our studies demonstrate that as a key
regulatory component of stress signaling, TRAF2 is
Figure 5 Impaired GCK expression in early-phase melanoma cells contributes to poor AP1/NF-kB activity and high level of
UVC-mediated apoptosis. (a) Western blot analysis of GCK and BclxL, BclxS levels in dierent melanoma cell lines. (b) Expression
of GCK and TRAF2 in melanocytes, early-stage (WM1650), intermediate-stage (WM35), and late-stage (LU1205) melanoma cells.
(c) GCK protein levels in WM1552 cells transfected by empty vector (control) or by GCK expression construct were determined by
Western analysis. LU1205 cell extract was used as a positive control. (d) Eect of GCK overexpression on AP-1-, ATF2- and NF-
kB-dependent transcription in WM1552 cells. (e) Eect of GCK expression on TNFa-mediated cell death. GCK alone or in the
indicated combination in the presence of GFP, was transfected into 56105 WM1552 cells. Cells were treated by TNFa+CHX 48 h
after transfection. Data reveal DNA fragmentation analysis of GFP+ cells. (f) Eect of GCK expression on UVC-mediated cell
death. GCK alone or in the indicated combination in the presence of GFP, was transfected into 56105 WM1552 cells. Cells were
treated by UVC (60 J/m2) 48 h after transfection and after subsequent 24 h subjected to analysis of PI+ in the total population of
GFP+ cells
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capable of altering UV-induced apoptosis, depending
on (a) its own availability, (b) expression of its
eectors, as shown here for GCK, and (c) the
availability of NF-kB, which contributes to the nature
of the apoptotic cascade (TNF/Fas signaling). Given
that alteration of apoptosis represents one of the
crucial targets in tumor development (Adams and
Cory, 1998; Bakker et al., 1999; Levine, 1997; Sprecher
et al., 1999), identifying regulatory components, as
shown here for TRAF2/GCK, points to additional
targets one may consider for design of therapeutic
means to treat this tumor type.
Materials and methods
Cell lines
Human melanoma LU1205 cells were maintained in
MCDB153/L15 medium (4 : 1) supplemented with 5% fetal
bovine serum, L-glutamine and antibiotics. LU1205/neo and
LU1205/TRAF2DN cell lines were maintained in the same
medium supplemented with G418 (200 mg/ml). In addition,
medium for WM1552 and WM1650 early-phase human
melanoma cells contained insulin (5 mg/ml). FEMX,
HHMSX and THX are human melanoma-derived cells which
were kindly provided by Øystein Fodstad and maintained in
RPMI1640 medium supplemented with 10% FCS. WM35
human melanoma cells were also maintained in RPMI1640
medium supplemented with 10% FCS. Cells were grown at
378C with 5% CO2.
Stable transfection and selection
The expression vector pcDNA3-FLAG-TRAF2DN encoding
the truncated form of TRAF2 cDNA without the first 86 aa
and (Relaix et al., 1998) was transfected by electroporation
(230V, 1050 mF) into LU1205 cells as previously described
(Ronai et al., 1998). In parallel, pcDNA3-neo vector
(Invitrogen, Carlsbad, CA) was transfected to generate
control LU1205-neo cells. The expression vector pCMV4-
IkBDN (Brockman et al., 1995) plus pcDNA3-neo was also
cotransfected by electroporation into LU1205 cells. LU1205/
neo, LU1205/TRAF2DN, and LU1205/IkBDN cell lines were
created as a mixed population of G418-resistant clones.
Transient transfection and luciferase assay
Transient transfection of dierent reporter constructs (0.25 –
0.5 mg) together with the indicated quantities of expression
vectors and pCMV-bgal (0.5 mg) into 56105 LU1205
melanoma cells was performed using Lipofectamine (GIB-
CO–BRL). The reporter constructs used were: 26NF-kB-
Luc (Zandi et al., 1997), 56Jun2tk-Luc, 56TRE-tk-Luc and
vector tk-Luc (van Dam et al., 1998). The expression
constructs pcDNA3-TRAF2, pcDNA3-FLAG-TRAF2DN
(Relaix et al., 1998), pCMV5-FLAG-GCK and GCK (K-H)
(Yuasa et al., 1998) were also used in these experiments. CAT
activity was determined as previously described (Ivanov et al.,
1995). Luciferase activity was determined using the Luciferase
assay system from Promega, Madison, WI, USA. CAT and
luciferase activities were normalized based on b-galactosidase
levels in transfected cells.
Transient transfection and GFP assay
Melanoma cells (56105) were transiently cotransfected with
expression vectors together with marker plasmid encoding
Green Fluorescent Protein, pGFP (1 mg and 0.25 mg,
respectively) using Lipofectamine (GIBCO–BRL). Forty
hours after transfection cells were irradiated with UVC
(40 J/m2) and 18 h after treatment were stained with
propidium iodide (PI) and analysed by flow cytometry. The
ratio of GFP+PI+/total GFP+ cells was used to measure
levels of cell death of transfected cells. Since analysis based
on GFP+PI+ cells consists of both apoptotic and necrotic
cells we refer to respective results as % of dead cells.
Important to note that given the certain toxicity of GFP the
overall basal level of apoptosis seen in GFP-based experi-
ments is higher than in other assays in which we monitored
cell death.
Treatment and apoptosis studies of stably transfected melanoma
cells
Cells were exposed to UVC at 60 J/m2 previously described
(Yang et al., 1996). Cycloheximide (10 mg/ml; Sigma, St.
Louis, MO) SB203580 (5 – 15 mM) (Calbiochem, San Diego,
CA, USA) and recombinant TNFa (1 – 10 ng/ml) (PharMin-
gen, San Diego, CA, USA) were used to treat melanoma
cells. Antagonistic monospecific antibodies against Fas (clone
G254-274), against TNFa (clone Mab1 from PharMingen),
Figure 6 Eects of dominant negative GCK on transcription
and apoptosis in LU1205 cells. (a) Percentage of dead cells that
were GFP and PI positive in LU1205 cells transfected with
dominant negative GCK (GCKK-H) and GFP 24 h after exposure
to UV-irradiation. (b) NF-kB transactivation was monitored
using 26NF-kB-Luc construct with GCKK-H at the indicated
concentrations, transfected into LU1205. (c) Analysis of luciferase
activity driven by 56Jun2tk-Luc reporter under conditions
described in (a)
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and against TNFR1 (clone 16803.1 from R&D Systems,
Minneapolis, MN, USA) were added as indicated at final
concentrations 1 – 10 mg/ml.
Annexin-V-FITC staining in the presence of PI was
performed for detection of apoptosis levels using a Annex-
in-V-FITC kit (PharMingen). Flow cytometric analysis was
performed on a FACscan or FACS Calibur flow cytometer
(Becton Dickinson), using Lysis II or CellQuest Software,
respectively.
DNA fragmentation analysis was performed as described
previously (Nicoletti et al., 1991). Cells were pelleted and
resuspended in 0.5 ml of hypotonic buer with 0.1% Triton
X-100 containing PI (40 mg/ml) and DNase-free RNase A
(1 mg/ml). Cells were incubated at 378C for 30 min and
analysed on a flow cytometer (Becton Dickinson). The
percentage of cells to the left of the diploid G0/1 peak,
characteristic of hypodiploid cells that have lost DNA, was
calculated as percentage of apoptosis cells and is referred to
in Results as % of apoptosis. Analysis was performed
without light scatter gating. DNA fragmentation analysis of
GFP positive cells was performed using cells fixed in 1%
paraformaldehyde, treated with 70% ethanol, washed with
PBS and stained with PI. Surface expression of Fas was
determined using anti-Fas-PE Ab (PharMingen CA) and flow
cytometric analysis.
Oligonucleotides and electrophoretic mobility shift assay
(EMSA)
Double-stranded oligonucleotides used in this study as
specific probes for transcription factor NF-kB, and the
method used for EMSA were described previously (Ivanov
et al., 1995). DNA-binding activities were quantified using
the BioRad Molecular Imaging system (model G5-250),
equipped with Molecular Analysis software (BioRad, Her-
cules, CA).
Western blotting analysis
Cell lysates (50 – 100 mg protein) were resolved on 10% SDS–
PAGE, transferred to nitrocellulose and processed according to
the standard manual. The polyclonal Abs used were Phospho-
MKK3/6 (Ser 189/207); Phospho-p38 (Thr180/Tyr182); Phos-
pho-ATF2 (Thr71); Phospho-SEK1/MKK4 (Thr223); Phos-
pho-MKK7; Phospho-JNK (Thr183/Tyr185); and Phospho-c-
Jun (Ser 63) from New England BioLabs. Polyclonal anti-
TRAF2 and anti-IkB (C-terminal) Abs were obtained from
Santa Cruz Biotechnology, CA, USA. Monoclonal anti-FasL
Ab was obtained from Transduction Laboratories, KY, USA.
Polyclonal anti-GCK Ab was previously described (Shi and
Kehrl, 1997). The primary Abs were used at dilution 1 : 1000 to
1 : 3000. The secondary abs were anti-rabbit or anti-mouse IgG
conjugated to horseradish peroxidase (dilution 1 : 5000).
Signals were detected using the ECL system (Amersham,
Arlington Heights).
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